We conducted a retrospective study to compare short- and mid-term patencies of Viabahn with surgical above-knee prosthetic bypass (pAKB).
Methods:
The records of 52 patients with either pAKB (n = 25) or Viabahn (n = 27) were reviewed. The majority had Rutherford clinical grade 3. Patients were followed after 3, 6, and 12 months and yearly thereafter.
Results:
For Viabahn, the short-term (1-16 months) primary patency rate was 60% with a secondary patency rate of 90%, and mid-term (1-68 months) patencies of 47% and 83.3%, respectively. In pAKB, the short-term results revealed a primary patency rate of 78% with a secondary patency of 91% and mid-term results of 65% and 90%, respectively. No statistical difference was found concerning short-term patencies. Mid-term primary patency was lower for Viabahn (P < .05) and secondary patency proved no significant difference.
Conclusion:
Viabahn revealed similar short-term primary and secondary patencies but lower mid-term primary patency. It provides a good alternative therapy to pAKB.
SaxonRRDakeMDVolgelzangRLKatzenBTBeckerGJ. Randomized, multicenter study comparing expanded polytetra-fluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19(6):823–832.
2.
GableD. Role of total endoluminal superficial femoral artery bypass. J Cardiovasc Surg (Torino). 2011;52(5):683–700.
3.
LammerJDakeMDBleynJ. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology. 2000;217(1):95–104.
4.
McQuadeKGableDHohmanSPearlGTheuneB.Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2009;49(1):109–115, 116.e1–9; discussion 116..
5.
JahnkeTAndresenRMüller-HülsbeckS. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. J Vasc Interv Radiol. 2003;14(1):41–51.
6.
FischerMSchwabeCSchulteKL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther. 2006;13(3):281–290.
7.
HartungOOteroADubucM. Efficacy of Hemobahn in the treatment of superficial femoral artery lesions in patients with acute or critical ischemia: a comparative study with claudicants. Eur J Vasc Endovasc Surg. 2005;30(3):300–306.
8.
AlimiYSHakamZHartungO. Efficacy of Viabahn in the treatment of severe superficial femoral artery lesions: which factors influence long-term patency?Eur J Vasc Endovasc Surg. 2008;35(3):346–352.
9.
FarrajNSrivastavaAPershadA. One-year outcomes for recanalization of long superficial femoral artery chronic total occlusions with the Viabahn stent graft. J Invasive Cardiol. 2009;21(6):278–281.
10.
KedoraJHohmannSGarrettWMunschaurCTheuneBGableD.Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J Vasc Surg. 2007;45(1):10–16; discussion 16.
11.
McQuadeKGableDPearlGTheuneBBlackS. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2010;52(3):584–590; discussion 590-1, 591.e1-591.e7.
12.
RutherfordRBBakerJDErnstC. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538.
13.
KumarKCrinnionJNAshleyWGGoughMJ. Conduit of choice for above-knee femoropopliteal bypass. British J Surg. 1995; 82(4): 556, Meeting Abstract.
14.
DonkerJMHoGHTe SlaaA. Midterm results of autologous saphenous vein and ePTFE pre-cuffed bypass surgery in peripheral arterial occlusive disease. Vasc Endovascular Surg. 2011;45(7):598–603.
15.
KlinkertPSchepersABurgerDHvan BockelJHBreslauPJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003;37(1):149–155.
16.
DorigoWPulliRPiffarettiG. Results from an Italian multicentric registry comparing heparin-bonded ePTFE graft and autologous saphenous vein in below-knee femoro-popliteal bypasses. J Cardiovasc Surg (Torino). 2012;53(2):187–194.
17.
TilanusHWObertopHVan UrkH.Saphenous vein or PTFE for femoropopliteal bypass. A prospective randomized trial. Ann Surg. 1985;202(6):780–782.
18.
KlinkertPPostPNBreslauPJvan BockelJH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004;27(4):357–362.
19.
TakagiHGotoSNMatsuiMManabeHUmemotoT. A contemporary meta-analysis of Dacron versus polytetrafluoroethylene grafts for femoropopliteal bypass grafting. J Vasc Surg. 2010;52(1):232–236.
20.
AbbottWMGreenRMMatsumotoT. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. J Vasc Surg. 1997;25(1):19–28.
21.
MetRVan LiendenKPKoelemayMJBipatSLegemateDAReekersJA. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc Intervent Radiol. 2008;31(4):687–697.
22.
SchillingerMSabetiSLoeweC. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888.
23.
LairdJRKatzenBTScheinertD. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.
24.
DickPWallnerHSabetiS. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74(7):1090–1095.
25.
SchlagerODickPSabetiS. Long-segment SFA stenting—the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12(6):676–684.
26.
SaxonRRCoffmanJMGoodingJMPonecDJ. Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions. J Vasc Interv Radiol. 2007;18(11):1341–1349.
27.
LentiMCieriEDe RangoP. Endovascular treatment of long lesions of the superficial femoral artery: results from a multicenter registry of a spiral, covered polytetrafluoroethylene stent. J Vasc Surg. 2007;45(1):32–39.
